Snehal G. Patel, William M. Lydiatt,
Christine M. Glastonbury, Suresh K. Mukherji,
Ronald A. Ghossein, Margaret Brandwein-Weber,
Brian O'Sullivan, and Jatin P. ShahStaging of carcinoma of the supraglottic, glottic, and subglottic larynx should use this system.<table>
<tr>
<th>These histopathologic types of cancer ...</th>
<th>Are staged according to the classification for ...</th>
<th>And can be found in chapter ...</th>
</tr>
<tr>
<td>Nonepithelial tumors of lymphoid tissue</td>
<td>Hematologic malignancies</td>
<td>78-83</td>
</tr>
<tr>
<td>Nonepithelial tumors of soft tissue</td>
<td>Soft tissue sarcoma of the head and neck</td>
<td>40</td>
</tr>
<tr>
<td>Nonepithelial tumors of bone and cartilage</td>
<td>Bone</td>
<td>38</td>
</tr>
<tr>
<td>Mucosal melanoma of the lip and oral cavity</td>
<td>Mucosal melanoma of the head and neck</td>
<td>14</td>
</tr>
</table><table>
<tr>
<th>Change</th>
<th>Details of Change</th>
<th>Level of Evidence</th>
</tr>
<tr>
<td>Anatomy - Primary Site(s)</td>
<td>Occult Primary Tumor: Staging of the patient who presents with Epstein-Barr virus (EBV)-unrelated and human papilloma virus (HPV)-unrelated metastatic cervical lymphadenopathy is not included in this chapter.</td>
<td>IV</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N)</td>
<td>There now are separate N staging approaches for HPV-related and HPV- unrelated cancers.</td>
<td>II1,2</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>There now are separate N category approaches for patients treated without cervical lymph node dissection (clinical N) and patients treated with cervical lymph neck dissection (pathological N).</td>
<td>II1,2</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>Extranodal extension (ENE) is introduced as a descriptor in all HPV-unrelated cancers.</td>
<td>II2</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>ENE in HPV negative cancers: Only clinically and radiographically overt ENE should be used for cN.</td>
<td>II2</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N) ☒</td>
<td>ENE in HPV negative cancers: Any pathologically detected ENE is considered ENE(+) and is used for pN.</td>
<td>II2</td>
</tr>
</table>  
To access the AJCC cancer staging forms, please visit www.cancerstaging.org.  
<!-- PageFooter="American College of Surgeons 2017 M.B. Amin et al. (eds.), AJCC Cancer Staging Manual, Eighth Edition, DOI 10.1007/978-3-319-40618-3_13" -->
<!-- PageNumber="149" -->
<!-- PageBreak -->  
<!-- PageNumber="150" -->
<!-- PageHeader="American Joint Committee on Cancer . 2017" -->  
<table>
<tr>
<th>Change</th>
<th>Details of Change</th>
<th>Level of Evidence</th>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N)</td>
<td>ENE in HPV-negative cancers: Presence of ENE is designated pN2a for a single ipsilateral node &lt;3 cm and pN3b for all other node(s).</td>
<td>II2</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N)</td>
<td>Classification of ENE: Clinically overt ENE is classified as ENE, and is considered ENE(+) for cN.</td>
<td>III3</td>
</tr>
<tr>
<td>Definition of Regional Lymph Node (N)</td>
<td>Classification of ENE: Pathologically detected ENE is classified as either ENEmi (≤2mm) or ENEma (&gt;2mm) for data collection purposes only, but both are considered ENE+ for definition of pN.</td>
<td>III3</td>
</tr>
</table><table>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
<tr>
<td>C10.1</td>
<td>Anterior (lingual) surface of epiglottis</td>
</tr>
<tr>
<td>C32.0</td>
<td>Glottis</td>
</tr>
<tr>
<td>C32.1</td>
<td>Supraglottis (laryngeal surface)</td>
</tr>
<tr>
<td>C32.2</td>
<td>Subglottis</td>
</tr>
<tr>
<td>C32.8</td>
<td>Overlapping lesion of larynx* *Stage by location of tumor bulk or epicenter</td>
</tr>
<tr>
<td>C32.9</td>
<td>Larynx, NOS* *Stage by location of tumor bulk or epicenter</td>
</tr>
</table>